organophosphonates has been researched along with fialuridine in 2 studies
| Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) | Studies (fialuridine) | Trials (fialuridine) | Recent Studies (post-2010) (fialuridine) |
|---|---|---|---|---|---|
| 9,968 | 880 | 3,596 | 157 | 5 | 21 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Clercq, E; Groen, J; Osterhaus, AD | 1 |
| Meinert, CL | 1 |
2 other study(ies) available for organophosphonates and fialuridine
| Article | Year |
|---|---|
Selective inhibitory effects of (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl) adenine and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil on seal herpesvirus (phocid herpesvirus 1) infection in vitro.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Cells, Cultured; Herpesviridae; Organophosphonates; Organophosphorus Compounds; Seals, Earless; Uridine | 1987 |
An open letter to the FDA regarding changes in reporting procedures for drugs and biologics proposed in the wake of the FIAU tragedy.
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Cost-Benefit Analysis; Cytosine; Drug Evaluation; Forms and Records Control; Humans; Organophosphonates; Organophosphorus Compounds; Safety Management; United States; United States Food and Drug Administration | 1996 |